The biological characteristics of glioma stem cells in human glioma             cell line SHG44.
Gliomas are the most common tumors of the central nervous system (CNS) and             a frequent cause of death. The treatment of malignant gliomas is often palliative             due to their high recurrence rate. A growing body of evidence suggests that glioma             may arise from cancer stem cells (CSC) correlated with neural stem cells (NSC),             with the capacity for self-renewal and multipotency. CSCs have been isolated from             human gliomas and numerous other solid tumors. It is assumed that a number of             established malignant cell lines also contain a rare subpopulation of stem cells.             This study was designed to investigate the proportion of CSCs in the human glioma             cell line SHG44 and to study the limitations of CD133 immunophenotyping in glioma             stem cell research. SHG44 cells were cultured in both serum-containing and serum-free             medium. The similar shape in growth curves (in the exponential growth phase) revealed             that most cells participated in the population amplification. Time gradient BrdU             labeling and monoclonal assay revealed that almost every single cell participated             in the division growth (98.82%) and possessed the ability to form clones (96.19%).             No significant difference was found in the proportions of CD133+ cells in the             serum-containing and serum-free groups (38.25%/37.92%). In addition, no significant             difference was noted in the proportions of CD133+ cells among monoclones selected             randomly in the serum-containing group. These results suggested that CD133- cells             generate CD133+ cells and have the ability to form clones. Thus, we concluded             that most SHG44 cells were CSCs and serum-free medium was not necessary for the             generation of CSCs. In this line, CD133- cells also possessed clonogenic, self-renewal             capacities and were also CSCs.
Department of Central Laboratory, Chaozhou Central Hospital, Chaozhou, Guangdong 521021, PR China.
Lei
L
Liu
Wen-Yu
WY
Li
Qiang
Q
Chen
Jia-Kun
JK
Zheng
Li-Ye
LY
Yang
D000071916:AC133 Antigen; D015703:Antigens, CD / Q000378:metabolism; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D005910:Glioma / Q000473:pathology*; D006023:Glycoproteins / Q000378:metabolism; D006801:Humans; D016130:Immunophenotyping; D014411:Neoplastic Stem Cells / Q000166:cytology* / Q000378:metabolism; D010455:Peptides / Q000378:metabolism
D000071916:AC133 Antigen; D015703:Antigens, CD; D006023:Glycoproteins; C000606023:PROM1 protein, human; D010455:Peptides